Analyst Edward Nash works at CANACCORD and is focused on the Healthcare sector with 193 price targets and ratings documented since 2014 spanning on 24 stocks. Analyst's average stock valuation to be materialised ratio is 46.06% with an average time for price targets to be met of 197.36 days.
Most recent stock forecast was given on CCXI, ChemoCentryx, Inc at 05-Aug-2022.
Edward Nash best performing recommendations are on BLUE (BLUEBIRD BIO, INC).
The best stock recommendation documented was for BLUE (BLUEBIRD BIO, INC) at 6/6/2017. The price target of $70 was fulfilled within 1 day with a profit of $6.43 (10.11%) receiving and performance score of 101.15.
Average potential price target upside